1
|
Monday, August 29 |
2:30-4:00PM |
Elizabeth J. K. Bhoj, MD, PhD
|
Diagnosis, Mechanism, and Targeted Treatment of Rare Disorders |
Pathogenic SPTBN1 variants cause an autosomal dominant neurodevelopmental syndrome
Supplement:
How many rare diseases are there?
|
2
|
Friday, September 9 |
2:30-4:00PM |
Mark Kahn, MD |
How tumor cells use lymphatic vessels and lymph nodes to reach the blood: New concepts in metastasis |
Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice
Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice
Supplement:
Molecular Basis of Metastasis
|
3
|
Friday, September 23 |
2:30-4:00PM |
Mark Sellmyer, MD, PhD |
Translational chemical biology: control of protein levels in vivo |
Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
Supplement:
Chimeric antigen receptor T‐cell therapy — assessment and management of toxicities
|
4
|
Friday, September 30 |
2:00-3:00PM |
Rajan Jain, MD
Rahul Kohli, MD, PhD |
Mentors and Mentees |
|
5
|
Monday, October 3 |
2:30-4:00PM |
Matthew Kayser, MD, PhD |
Making connections between sleep and loneliness |
Chronic social isolation signals starvation and reduces sleep in Drosophila
Supplements:
Sleep, insomnia, and depression
The growing problem of loneliness
|
6
|
Monday, October 17 |
2:30-4:00PM |
Joshua Franklin, MD, PhD |
Ethnographic and cross-cultural approaches to psychosis and other unshared experiences |
Beyond Trauma: A Multiple Pathways Approach to Auditory Hallucinations in Clinical and Nonclinical Populations
Supplement:
"Introduction" from Our Most Troubling Madness : Case Studies in Schizophrenia Across Cultures
|
7
|
Friday, October 21 |
2:30-4:00PM |
Richard Phillips, MD, PhD |
Epigenetic mechanisms driving malignant transformation of neural cells |
Insulator dysfunction and oncogene activation in IDH mutant gliomas
Supplement:
Glioma
|
8
|
Monday, October 24 |
2:30-4:00PM |
Vikram Paralkar, MD |
Targeting the Leukemia Epigenome |
Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo
Supplements:
Therapeutic implications of menin inhibition in acute leukemias
The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
|
9
|
Monday, October 31 |
2:30-4:00PM |
Marco Ruella, MD |
Targeting cytokine release syndrome associated with CAR-T therapy |
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Data: Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Supplements:
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
|
10
|
Friday, November 18 |
2:30-4:00PM |
Katharine Bar, MD
|
Engineering B cells to Neutralize HIV |
In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice
|
11
|
Monday, November 21 |
2:30-4:00PM |
Jonathan Miner, MD, PhD |
Single gene mutations associated with severe COVID19
|
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Supplement:
Severe Covid-19
|
12
|
Monday, November 28 |
2:30-4:00PM |
Sharlene Day, MD |
Clonal hematopoiesis of indeterminate potential (CHIP) in atherosclerotic heart disease |
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
Supplement:
Inflammation during the life cycle of the atherosclerotic plaque
|
